Search Results - "Lacasce, Ann"

The International Prognostic Index: still relevant 30 years later by LaCasce, Ann S

Get full text

Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease by LaCasce, Ann S.

“…Although the majority of patients with Hodgkin lymphoma are cured with initial therapy, 10% to 15% of patients with early stage disease and 15% to 30% of…”
Get full text

Current considerations in AYA Hodgkin lymphoma by Crombie, Jennifer L., LaCasce, Ann S.

“…Summary Hodgkin lymphoma (HL) commonly occurs in adolescents and young adults (AYA), defined by the National Cancer Institute as people diagnosed with cancer…”
Get full text

Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders by Crombie, Jennifer L, LaCasce, Ann S

“…Epstein-Barr virus (EBV) is a ubiquitous herpesvirus, affecting up to 90% of the population. EBV was first identified as an oncogenic virus in a Burkitt…”
Get full text

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma by LaCasce, Ann S., Bociek, R. Gregory, Sawas, Ahmed, Caimi, Paolo, Agura, Edward, Matous, Jeffrey, Ansell, Stephen M., Crosswell, Howland E., Islas-Ohlmayer, Miguel, Behler, Caroline, Cheung, Eric, Forero-Torres, Andres, Vose, Julie, O'Connor, Owen A., Josephson, Neil, Wang, Yinghui, Advani, Ranjana

“…Autologous stem cell transplantation (ASCT) is standard of care for patients with Hodgkin lymphoma (HL) who have relapsed/refractory disease after frontline…”
Get full text

Improved survival in cHL with novel agents by Merryman, Reid W., LaCasce, Ann S.

Get full text

Evolving management of patients with double-hit lymphoma by LaCasce, Ann S

Get full text

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma by Advani, Ranjana, Flinn, Ian, Popplewell, Leslie, Forero, Andres, Bartlett, Nancy L, Ghosh, Nilanjan, Kline, Justin, Roschewski, Mark, LaCasce, Ann, Collins, Graham P, Tran, Thu, Lynn, Judith, Chen, James Y, Volkmer, Jens-Peter, Agoram, Balaji, Huang, Jie, Majeti, Ravindra, Weissman, Irving L, Takimoto, Chris H, Chao, Mark P, Smith, Sonali M

“…An antibody to CD47 used in combination with rituximab induced responses in half of a small group of patients with refractory B-cell lymphoma. Inhibiting the…”
Get full text

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results by Advani, Ranjana H., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Christian, Beth A., Ansell, Stephen M., Moskowitz, Craig H., Brown, Lisa, Zhang, Chiyu, Taft, David, Ansari, Sahar, Sacchi, Mariana, Ho, Linda, Herrera, Alex F.

“…This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r)…”
Get full text

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma by Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.

“…In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with…”
Get full text

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma by Gibson, Christopher J, Lindsley, R Coleman, Tchekmedyian, Vatche, Mar, Brenton G, Shi, Jiantao, Jaiswal, Siddhartha, Bosworth, Alysia, Francisco, Liton, He, Jianbo, Bansal, Anita, Morgan, Elizabeth A, Lacasce, Ann S, Freedman, Arnold S, Fisher, David C, Jacobsen, Eric, Armand, Philippe, Alyea, Edwin P, Koreth, John, Ho, Vincent, Soiffer, Robert J, Antin, Joseph H, Ritz, Jerome, Nikiforow, Sarah, Forman, Stephen J, Michor, Franziska, Neuberg, Donna, Bhatia, Ravi, Bhatia, Smita, Ebert, Benjamin L

“…Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood of otherwise healthy…”
Get full text

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era by Zhou, Zheng, Sehn, Laurie H., Rademaker, Alfred W., Gordon, Leo I., LaCasce, Ann S., Crosby-Thompson, Allison, Vanderplas, Ann, Zelenetz, Andrew D., Abel, Gregory A., Rodriguez, Maria A., Nademanee, Auayporn, Kaminski, Mark S., Czuczman, Myron S., Millenson, Michael, Niland, Joyce, Gascoyne, Randy D., Connors, Joseph M., Friedberg, Jonathan W., Winter, Jane N.

“…The International Prognostic Index (IPI) has been the basis for determining prognosis in patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20…”
Get full text

Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events by Singer, Sean, Tan, Sally Y., Dewan, Anna K., Davids, Matthew, LaCasce, Ann S., Treon, Steven P., LeBoeuf, Nicole R.

“…Ibrutinib is an oral inhibitor of Bruton tyrosine kinase that is approved by the United States Food and Drug Administration for several lymphoproliferative…”
Get full text

PI3K inhibitors in haematological malignancies by Brown, Jennifer R, Danilov, Alexey V, LaCasce, Ann S, Davids, Matthew S

“…Two of the three original idelalisib randomised registration trials in patients with relapsed chronic lymphocytic leukaemia showed both progression-free…”
Get full text

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma by Stephens, Deborah M., Li, Hongli, Schöder, Heiko, Straus, David J., Moskowitz, Craig H., LeBlanc, Michael, Rimsza, Lisa M., Bartlett, Nancy L., Evens, Andrew M., LaCasce, Ann S., Barr, Paul M., Knopp, Michael V., Hsi, Eric D., Leonard, John P., Kahl, Brad S., Smith, Sonali M., Friedberg, Jonathan W.

“…Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography…”
Get full text

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity by Wilson, Wyndham H, Prof, O'Connor, Owen A, Prof, Czuczman, Myron S, Prof, LaCasce, Ann S, MD, Gerecitano, John F, MD, Leonard, John P, Prof, Tulpule, Anil, MD, Dunleavy, Kieron, MD, Xiong, Hao, PhD, Chiu, Yi-Lin, PhD, Cui, Yue, PhD, Busman, Todd, MS, Elmore, Steven W, PhD, Rosenberg, Saul H, PhD, Krivoshik, Andrew P, MD, Enschede, Sari H, MD, Humerickhouse, Rod A, MD

“…Summary Background Proteins of the BCL-2 family regulate clonal selection and survival of lymphocytes, and are frequently overexpressed in lymphomas…”
Get full text

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study by Davids, Matthew S, Lampson, Benjamin L, Tyekucheva, Svitlana, Wang, Zixu, Lowney, Jessica C, Pazienza, Samantha, Montegaard, Josie, Patterson, Victoria, Weinstock, Matthew, Crombie, Jennifer L, Ng, Samuel Y, Kim, Austin I, Jacobson, Caron A, LaCasce, Ann S, Armand, Philippe, Arnason, Jon E, Fisher, David C, Brown, Jennifer R

“…Both continuous therapy with acalabrutinib and fixed-duration therapy with venetoclax–obinutuzumab are effective for previously untreated chronic lymphocytic…”
Get full text

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation by Armand, Philippe, Chen, Yi-Bin, Redd, Robert A., Joyce, Robin M., Bsat, Jad, Jeter, Erin, Merryman, Reid W., Coleman, Kimberly C., Dahi, Parastoo B., Nieto, Yago, LaCasce, Ann S., Fisher, David C., Ng, Samuel Y., Odejide, Oreofe O., Freedman, Arnold S., Kim, Austin I., Crombie, Jennifer L., Jacobson, Caron A., Jacobsen, Eric D., Wong, Jeffrey L., Patel, Sanjay S., Ritz, Jerome, Rodig, Scott J., Shipp, Margaret A., Herrera, Alex F.

“…Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) who…”
Get full text

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial by Neilan, Tomas G, Quinaglia, Thiago, Onoue, Takeshi, Mahmood, Syed S, Drobni, Zsofia D, Gilman, Hannah K, Smith, Amanda, Heemelaar, Julius C, Brahmbhatt, Priya, Ho, Jor Sam, Sama, Supraja, Svoboda, Jakub, Neuberg, Donna S, Abramson, Jeremy S, Hochberg, Ephraim P, Barnes, Jefferey A, Armand, Philippe, Jacobsen, Eric D, Jacobson, Caron A, Kim, Austin I, Soumerai, Jacob D, Han, Yuchi, Friedman, Robb S, Lacasce, Ann S, Ky, Bonnie, Landsburg, Dan, Nasta, Sunita, Kwong, Raymond Y, Jerosch-Herold, Michael, Redd, Robert A, Hua, Lanqi, Januzzi, James L, Asnani, Aarti, Mousavi, Negareh, Scherrer-Crosbie, Marielle

“…IMPORTANCE: Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with…”
Get full text

Evidence-Based Minireview: What is the optimal timing of anti-PD-1 antibodies in relapsed classical Hodgkin lymphoma? by Allen, Pamela Blair, LaCasce, Ann S

“…A 26-year-old woman was initially diagnosed with stage III classical Hodgkin lymphoma (HL) treated with doxorubicin, bleomycin, vinblastine, and dacarbazine…”
Get full text